Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Genetic models of Pancreatic Neuroendocrine Tumours

FY 2012-13

Summary
Recent advances have highlighted that cancer represents a collection of diseases, differing not only in the location or organ of disease but the fundamental makeup of the tumours. To advance treatment options and approaches, a better understanding of the underlying causes of disease is essential. DNA and genome-based sequencing studies have revealed a number of differences between normal and tumour cells, and from this we can draw associations about how cancers arise. It is, however, essential to test these associations in a laboratory and experimental setting in order to be able to identify the changes that actually drive cancers to develop, as these will provide the best opportunities to develop novel drugs or therapies. One recent sequencing study of the second most common type of pancreatic cancer, pancreatic neuroendocrine tumours (PNETs), revealed a number of new players in these cancers. Specifically, 43% of patients showed mutations in either DAXX or ATRX. Interestingly, this was the first report to suggest a role for DAXX in cancer. DAXX and ATRX work to together to help maintain DNA integrity. As it is well established that a loss of DNA integrity can contribute to cancer development, our work aims to test the hypothesis that DAXX loss is an important for the formation of a subset of PNETs. To address this, we aim to develop a mouse model for PNETs through the specific loss of DAXX in the pancreas. We will also study how other changes common in cancers contribute to the development of PNETs in this model. Not only will our models of PNETs teach us a great deal about how these cancers arise, they will also provide a tool in which we can start to study what treatment options are most effective for these tumours, having a direct role in advancing patient care. Combined, through this work and a better understanding of the key changes that drive these cancers we aim to advance diagnosis and treatments options for patients with PNETs.
Program
CIHR Fellowship
Location
Texas, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
282473
Name
Wasylishen Amanda R
Region
Texas
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Genetic models of Pancreatic Neuroendocrine Tumours
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Genetics; Chromatin Modifiers; Daxx; Epigenetics; Mdm2; P53
Abstract
Recent advances have highlighted that cancer represents a collection of diseases, differing not only in the location or organ of disease but the fundamental makeup of the tumours. To advance treatment options and approaches, a better understanding of the underlying causes of disease is essential. DNA and genome-based sequencing studies have revealed a number of differences between normal and tumour cells, and from this we can draw associations about how cancers arise. It is, however, essential to test these associations in a laboratory and experimental setting in order to be able to identify the changes that actually drive cancers to develop, as these will provide the best opportunities to develop novel drugs or therapies. One recent sequencing study of the second most common type of pancreatic cancer, pancreatic neuroendocrine tumours (PNETs), revealed a number of new players in these cancers. Specifically, 43% of patients showed mutations in either DAXX or ATRX. Interestingly, this was the first report to suggest a role for DAXX in cancer. DAXX and ATRX work to together to help maintain DNA integrity. As it is well established that a loss of DNA integrity can contribute to cancer development, our work aims to test the hypothesis that DAXX loss is an important for the formation of a subset of PNETs. To address this, we aim to develop a mouse model for PNETs through the specific loss of DAXX in the pancreas. We will also study how other changes common in cancers contribute to the development of PNETs in this model. Not only will our models of PNETs teach us a great deal about how these cancers arise, they will also provide a tool in which we can start to study what treatment options are most effective for these tumours, having a direct role in advancing patient care. Combined, through this work and a better understanding of the key changes that drive these cancers we aim to advance diagnosis and treatments options for patients with PNETs.
Competitiondate
201302
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wasylishen, Amanda R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2012-13) | Canada Spends